The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.

Mohammed Al-Hamadani, Thomas M. Habermann, James R. Cerhan, William R. Macon, Matthew J. Maurer, Ronald S. Go, Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology. ,vol. 90, pp. 790- 795 ,(2015) , 10.1002/AJH.24086

J. F. Seymour, M. Pfreundschuh, M. Trneny, L. H. Sehn, J. Catalano, E. Csinady, N. Moore, B. Coiffier, , R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes Haematologica. ,vol. 99, pp. 1343- 1349 ,(2014) , 10.3324/HAEMATOL.2013.100818

Bertrand Coiffier, Eric Lepage, Josette Brière, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma The New England Journal of Medicine. ,vol. 346, pp. 235- 242 ,(2002) , 10.1056/NEJMOA011795

Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Mathias Haenel, Peter Borchmann, Christian Schmidt, Andreas Viardot, Martin Bentz, Norma Peter, Gerhard Ehninger, Gottfried Doelken, Christian Ruebe, Lorenz Truemper, Andreas Rosenwald, Michael Pfreundschuh, Markus Loeffler, Bertram Glass, Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1) Lancet Oncology. ,vol. 13, pp. 1250- 1259 ,(2012) , 10.1016/S1470-2045(12)70481-3

Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, Rudolf Schmits, Martin Mohren, Eva Lengfelder, Marcel Reiser, Christina Nickenig, Michael Clemens, Norma Peter, Carsten Bokemeyer, Hartmut Eimermacher, Anthony Ho, Martin Hoffmann, Roland Mertelsmann, Lorenz Trümper, Leopold Balleisen, Ruediger Liersch, Bernd Metzner, Frank Hartmann, Bertram Glass, Viola Poeschel, Norbert Schmitz, Christian Ruebe, Alfred C Feller, Markus Loeffler, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncology. ,vol. 9, pp. 105- 116 ,(2008) , 10.1016/S1470-2045(08)70002-0

C. Haioun, N. Mounier, J.F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Récher, C. Fermé, J. Gabarre, R. Herbrecht, F. Morchhauser, C. Gisselbrecht, Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Annals of Oncology. ,vol. 20, pp. 1985- 1992 ,(2009) , 10.1093/ANNONC/MDP237

Francesco Merli, Stefano Luminari, Giuseppe Rossi, Caterina Mammi, Luigi Marcheselli, Alessandra Tucci, Fiorella Ilariucci, Annalisa Chiappella, Maurizio Musso, Alice Di Rocco, Caterina Stelitano, Isabel Alvarez, Luca Baldini, Patrizio Mazza, Flavia Salvi, Annalisa Arcari, Alberto Fragasso, Paolo G. Gobbi, Anna Marina Liberati, Massimo Federico, Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi Leukemia & Lymphoma. ,vol. 53, pp. 581- 588 ,(2012) , 10.3109/10428194.2011.621565

Christian Récher, Bertrand Coiffier, Corinne Haioun, Thierry Jo Molina, Christophe Fermé, Olivier Casasnovas, Catherine Thiéblemont, André Bosly, Guy Laurent, Franck Morschhauser, Hervé Ghesquières, Fabrice Jardin, Serge Bologna, Christophe Fruchart, Bernadette Corront, Jean Gabarre, Christophe Bonnet, Maud Janvier, Danielle Canioni, Jean-Philippe Jais, Gilles Salles, Hervé Tilly, Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. The Lancet. ,vol. 378, pp. 1858- 1867 ,(2011) , 10.1016/S0140-6736(11)61040-4

N. Ketterer, B. Coiffier, C. Thieblemont, C. Fermé, J. Brière, O. Casasnovas, S. Bologna, B. Christian, T. Connerotte, C. Récher, D. Bordessoule, C. Fruchart, R. Delarue, C. Bonnet, F. Morschhauser, B. Anglaret, C. Soussain, B. Fabiani, H. Tilly, C. Haioun, Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) Annals of Oncology. ,vol. 24, pp. 1032- 1037 ,(2013) , 10.1093/ANNONC/MDS600

Qian Shi, Aimery de Gramont, Axel Grothey, John Zalcberg, Benoist Chibaudel, Hans-Joachim Schmoll, Matthew T. Seymour, Richard Adams, Leonard Saltz, Richard M. Goldberg, Cornelis J.A. Punt, Jean-Yves Douillard, Paulo M. Hoff, Joel Randolph Hecht, Herbert Hurwitz, Eduardo Díaz-Rubio, Rainer Porschen, Niall C. Tebbutt, Charles Fuchs, John Souglakos, Alfredo Falcone, Christophe Tournigand, Fairooz F. Kabbinavar, Volker Heinemann, Eric Van Cutsem, Carsten Bokemeyer, Marc Buyse, Daniel J. Sargent, Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database Journal of Clinical Oncology. ,vol. 33, pp. 22- 28 ,(2015) , 10.1200/JCO.2014.56.5887